publication date: Oct. 31, 2014
20141031 - Oct. 31, 2014
ISSUE 41 – OCT. 31, 2014PDF

How Elite Institutions Were Affected By A Decade of Constricted Funding

The ten-year period of erosion that followed the doubling of the NIH budget has hit some research institutions harder than others.

NIH appropriations figures provide a glimpse of the state of science funding in the U.S., but they don’t shed light on how individual institutions and areas of research are affected.

To conduct an exploratory analysis of levels of funding at specific institutions, The Cancer Letter compiled NIH and NCI funding figures from 2003 to 2013 for eight freestanding cancer centers and nine other research institutions that include cancer centers. A focus on freestanding cancer centers provides a snapshot of funding at institutions engaged primarily in basic and clinical cancer research.

 The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

The Cancer Letter asked leaders of cancer centers, professional societies, and science advocacy organizations to comment on declining levels of NIH and NCI funding at freestanding cancer centers and selected academic institutions that include cancer centers.

Guest Editorial
The Academic Difference: George Weiner On How America’s Cancer Centers Are More Valuable Than Ever

“The nation’s academic cancer centers are a national resource that will increase in value as remarkable changes continue in biomedical research, cancer care, and health policy.”

Bennett, Federal Prosecutors Reach $475,000 Settlement

Charles Bennett, an oncologist and cancer researcher whose work focuses on adverse events caused by pharmaceutical products, settled a federal complaint brought by a whistleblower alleging irregularities in the management of R01 research grants administered by Northwestern University. 

Northwestern paid $2.93 million in 2013 to settle allegations of mismanaging five of Bennett’s R01 grants. 

Funding Opportunity
Leukemia & Lymphoma Society Launches Myeloid Program

The Leukemia & Lymphoma Society launched a program to fund research projects focused on myeloid diseases, such as myelodysplastic syndromes and myeloproliferative neoplasms, both of which can progress to acute myeloid leukemia. 

photoIn Brief

  • City of Hope launches Hematologic Malignancies and Stem Cell Transplantation Institute

  • Lisa Richardson named director of CDC Division of Cancer Prevention and Control

  • Milan Mrksich named associate director for research technology and infrastructure at Lurie Cancer Center

  • Ronan Swords receives Pap Corps Endowed Professorship

  • Laura Brod named CEO of GeneSegues Therapeutics

  • Merck Serono names three grant winners

  • Martine Extermann receives top award from International Society of Geriatric Oncology

  • Aptose Biosciences Inc. joins Beat AML consortium

  • Meridian Health and Hackensack University Health Network to discuss merging health systems

  • Knight Cancer Institute at Oregon Health and Science University launches statewide program

  • American Society of Clinical Oncology endorses AUA/ASTRO Guideline

photoDrugs and Targets

  • FDA extends Lymphoseek label to include mapping in solid tumors

  • National Comprehensive Cancer Network approves VeriStrat predictive proteomics test

  • Myriad Genetics establishes European laboratory

  • Case Medical Center and Seidman Cancer Center select GenomOncology for workflow management

  • Qiagen and Astellas Pharma to collaborate on companion diagnostics

Copyright (c) 2020 The Cancer Letter Inc.